Please login to the form below

Not currently logged in
Email:
Password:

Element of Pfizer's Viagra patent rejected

The US Patent and Trademark Office has partially rejected Pfizer's patent claim on Viagra due to similarities to a Chinese herb

An appeals board within the US Patent and Trademark Office has partially rejected Pfizer's patent claim on its erectile dysfunction drug, Viagra (sildenafil), ruling that an element of the drug was not significantly different to the Chinese medicine, Yin Yang Huo (Horny Goat Weed), and did not represent a new invention.

In coming to its conclusion on the ruling, the appeals board stated that the patent claim was the next logical step up from using Yin Yang Huo in the treatment of erectile dysfunction. A chemical ingredient of the herb was found to be similar to an enzyme inhibitor found in Viagra.

The claim formed part of a 2002 lawsuit filed by Pfizer against Eli Lilly over its rival drug, Cialis. Pfizer has until April 12, to seek a rehearing or appeal against the decision.

The patent in question is due to expire in 2019. This ruling only concerns one element of Viagra, and Pfizer could therefore still use the patent to block generic competition from the duplication of the drug's active ingredient (sildenafil citrate).

Pfizer's revenue for 2009 included $1.89bn from the sale of Viagra.

17th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics